Maxzimaa Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.50 M
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 36.08%
- Profit Growth 2425.57%
- Ebitda 181.84%
- Net Worth 1.65%
- Total Assets 44.53%
About Maxzimaa Pharmaceuticals
Maxzimaa Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 December 2014 and has a history of Ten years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Lovpreet Moti, Sucheta Dhawan, Dhiraj Joshi, and One other member serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100DL2014PTC274793
-
Company No.
274793
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Dec 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Maxzimaa Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lovpreet Moti
|
Director | 20-Jan-2015 | Current |
|
Sucheta Dhawan
|
Director | 20-Jan-2015 | Current |
|
Dhiraj Joshi
|
Director | 20-Jan-2015 | Current |
|
Rachana Khatri
|
Director | 18-Oct-2018 | Current |
Financial Performance of Maxzimaa Pharmaceuticals.
Maxzimaa Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.08% increase. The company also saw a substantial improvement in profitability, with a 2425.57% increase in profit. The company's net worth moved up by a moderate rise of 1.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxzimaa Pharmaceuticals?
In 2023, Maxzimaa Pharmaceuticals had a public holding of 96.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Maxzima Medicare Private LimitedSucheta Dhawan is a mutual person
-
Fortem Security Private Limited
Sucheta Dhawan is a mutual person
-
Nuri Sciences Private Limited
Dhiraj Joshi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxzimaa Pharmaceuticals?
Maxzimaa Pharmaceuticals has a workforce of 57 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxzimaa Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxzimaa Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
